Document is current
Any future updates will be listed below
-
Authors
Bange, Erin M.
Han, Nicholas A. https://orcid.org/0000-0003-1410-9931
Wileyto, Paul
Kim, Justin Y. https://orcid.org/0000-0003-0774-8137
Gouma, Sigrid https://orcid.org/0000-0002-7853-8340
Robinson, James
Greenplate, Allison R.
Hwee, Madeline A.
Porterfield, Florence
Owoyemi, Olutosin https://orcid.org/0000-0002-7527-5768
Naik, Karan
Zheng, Cathy https://orcid.org/0000-0002-0092-5463
Galantino, Michael
Weisman, Ariel R. https://orcid.org/0000-0002-7187-304X
Ittner, Caroline A. G.
Kugler, Emily M.
Baxter, Amy E. https://orcid.org/0000-0002-1555-0713
Oniyide, Olutwatosin
Agyekum, Roseline S. https://orcid.org/0000-0001-7145-5609
Dunn, Thomas G.
Jones, Tiffanie K.
Giannini, Heather M. https://orcid.org/0000-0002-8979-3806
Weirick, Madison E.
McAllister, Christopher M.
Babady, N. Esther
Kumar, Anita
Widman, Adam J.
DeWolf, Susan
Boutemine, Sawsan R.
Roberts, Charlotte
Budzik, Krista R.
Tollett, Susan
Wright, Carla
Perloff, Tara
Sun, Lova
Mathew, Divij https://orcid.org/0000-0002-8323-7358
Giles, Josephine R.
Oldridge, Derek A. https://orcid.org/0000-0003-2177-5633
Wu, Jennifer E.
Alanio, Cécile https://orcid.org/0000-0003-2785-7445
Adamski, Sharon
Garfall, Alfred L.
Vella, Laura A.
Kerr, Samuel J.
Cohen, Justine V.
Oyer, Randall A. https://orcid.org/0000-0001-7554-4166
Massa, Ryan
Maillard, Ivan P.
Maxwell, Kara N. https://orcid.org/0000-0001-8192-4202
Reilly, John P. https://orcid.org/0000-0003-3937-5320
Maslak, Peter G.
Vonderheide, Robert H.
Wolchok, Jedd D. https://orcid.org/0000-0001-6718-2222
Hensley, Scott E. https://orcid.org/0000-0002-2928-7506
Wherry, E. John https://orcid.org/0000-0003-0477-1956
Meyer, Nuala J. https://orcid.org/0000-0003-4597-5584
DeMichele, Angela M. https://orcid.org/0000-0003-1297-4251
Vardhana, Santosha A. https://orcid.org/0000-0002-3100-1298
Mamtani, Ronac https://orcid.org/0000-0002-8267-5356
Huang, Alexander C. https://orcid.org/0000-0002-0099-0492
- License Information
-
More Information
Article History
Received: 27 January 2021
Accepted: 6 May 2021
First Online: 20 May 2021
Competing interests
: S.A.V. is a consultant for Immunai and ADC Therapeutics. A.C.H. is a consultant for Immunai and has received research support from Bristol Myers Squibb. R.H.V. reports having received consulting fees from Medimmune and Verastem and research funding from Fibrogen, Janssen and Eli Lilly. R.H.V. is an inventor on licensed patents relating to cancer cellular immunotherapy and cancer vaccines and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. J.W. is serving as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, Astellas, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Chugai, Elucida, Eli Lilly, F-Star, Genentech, Imvaq, Janssen, Kyowa Hakko Kirin, Kleo Pharmaceuticals, Linnaeus, MedImmune, Merck, Neon Therapeutics, Northern Biologics, Ono, Polaris Pharma, Polynoma, PsiOxus, PureTech, Recepta, Takara Bio, Trieza, Sellas Life Sciences, Serametrix, Surface Oncology, Syndax and Synthologic. J.W. received research support from Bristol Myers Squibb, MedImmune, Merck and Genentech and has equity in Potenza Therapeutics, Tizona Pharmaceuticals, Adaptive Biotechnologies, Elucida, Imvaq, BeiGene, Trieza and Linnaeus. J.V.C. is serving as a consultant for Sanofi-Genzyme and Bristol Myers Squibb. A.M.D. is supported with an honorarium from Pfizer (2016 and 2018), consulting fees from Context Therapeutics (2018), Novartis (2016) and Calithera (2016) and institutional research support from Novartis, Pfizer, Genetech, Calithera and Menarini. R.M. has served as a consultant for Seattle Genetics, Astellas and Roche; has received research funding from Merck; and received funding from Flatiron Health for speaking on Real-World Evidence. A.L.G. received research funding from Novartis, Janssen, Tmunity and CRISPR Therapeutics and honoraria from Janssen and GlaxoSmithKline. All other authors declare no competing financial interests.
Free to read: This content has been made available to all.
